J Korean Assoc Oral Maxillofac Surg.  2018 Dec;44(6):289-292. 10.5125/jkaoms.2018.44.6.289.

Gingival crevicular fluid levels of sclerostin in chronic periodontitis and healthy subjects

• Rezaei Esfahrood Z
• Yadegari Z
• Veysari SK
• Kadkhodazadeh M

• KMID: 2467176
• DOI: http://doi.org/10.5125/jkaoms.2018.44.6.289

Abstract

OBJECTIVES
Chronic periodontitis is a common inflammatory disease of the oral cavity that causes destruction of periodontal tissues and bone around the teeth. Sclerostin is a protein encoded by the SOST gene. In this study, gingival crevicular fluid (GCF) levels of sclerostin in patients with chronic periodontitis were compared with those of healthy subjects.
MATERIALS AND METHODS
In this case-control study, a total of 40 subjects were enrolled and divided into the healthy group (n=23) and chronic periodontitis group (n=17). GCF samples were collected, and the concentration of sclerostin was evaluated using enzyme-linked immunosorbent assay. Comparison of significance between groups was assessed using Mann-Whitney U test.
RESULTS
Sclerostin concentration was significantly higher in the chronic periodontitis group compared with the healthy group (P < 0.005).
CONCLUSION
Despite the limitations of this study, sclerostin can be a possible marker for assessment of periodontal health status.

Keyword

Sclerostin; Periodontitis; Gingival crevicular fluid

MeSH Terms

Case-Control Studies
Chronic Periodontitis*
Enzyme-Linked Immunosorbent Assay
Gingival Crevicular Fluid*
Healthy Volunteers*
Humans
Mouth
Periodontitis
Tooth

Figure

• 

  Fig. 1 Box plot of sclerostin levels in healthy subjects and patients with chronic periodontitis.

Reference

1. Kornman KS, Page RC, Tonetti MS. The host response to the microbial challenge in periodontitis: assembling the players. Periodontol 2000. 1997; 14:33–53. PMID: 9567965.

2. Bascones-Martínez A, Muñoz-Corcuera M, Noronha S, Mota P, Bascones-Ilundain C, Campo-Trapero J. Host defence mechanisms against bacterial aggression in periodontal disease: basic mechanisms. Med Oral Patol Oral Cir Bucal. 2009; 14:e680–e685. PMID: 19680192.

3. Kumar PS, Griffen AL, Barton JA, Paster BJ, Moeschberger ML, Leys EJ. New bacterial species associated with chronic periodontitis. J Dent Res. 2003; 82:338–344. PMID: 12709498.

4. Buduneli N, Kinane DF. Host-derived diagnostic markers related to soft tissue destruction and bone degradation in periodontitis. J Clin Periodontol. 2011; 38(Suppl 11):85–105. PMID: 21323706.

5. Champagne CM, Buchanan W, Reddy MS, Preisser JS, Beck JD, Offenbacher S. Potential for gingival crevice fluid measures as predictors of risk for periodontal diseases. Periodontol 2000. 2003; 31:167–180. PMID: 12657001.

6. Robling AG, Niziolek PJ, Baldridge LA, Condon KW, Allen MR, Alam I, et al. Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost/sclerostin. J Biol Chem. 2008; 283:5866–5875. PMID: 18089564.

7. Winkler DG, Sutherland MK, Geoghegan JC, Yu C, Hayes T, Skonier JE, et al. Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J. 2003; 22:6267–6276. PMID: 14633986.

8. Silverman SL. Sclerostin. J Osteoporos. 2010; 2010:941419. PMID: 20981340.

9. Poole KE, van Bezooijen RL, Loveridge N, Hamersma H, Papapoulos SE, Löwik CW, et al. Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. FASEB J. 2005; 19:1842–1844. PMID: 16123173.

10. Atkins GJ, Rowe PS, Lim HP, Welldon KJ, Ormsby R, Wijenayaka AR, et al. Sclerostin is a locally acting regulator of late-osteoblast/preosteocyte differentiation and regulates mineralization through a MEPE-ASARM-dependent mechanism. J Bone Miner Res. 2011; 26:1425–1436. PMID: 21312267.

11. Ren Y, Han X, Ho SP, Harris SE, Cao Z, Economides AN, et al. Removal of SOST or blocking its product sclerostin rescues defects in the periodontitis mouse model. FASEB J. 2015; 29:2702–2711. PMID: 25757567.

12. Balli U, Aydogdu A, Dede FO, Turer CC, Guven B. Gingival crevicular fluid levels of sclerostin, osteoprotegerin, and receptor activator of nuclear factor-κB ligand in periodontitis. J Periodontol. 2015; 86:1396–1404. PMID: 26367496.

13. Li X, Ominsky MS, Niu QT, Sun N, Daugherty B, D'Agostin D, et al. Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J Bone Miner Res. 2008; 23:860–869. PMID: 18269310.

14. Griffiths GS. Formation, collection and significance of gingival crevice fluid. Periodontol 2000. 2003; 31:32–42. PMID: 12656994.

15. Li X, Ominsky MS, Warmington KS, Morony S, Gong J, Cao J, et al. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res. 2009; 24:578–588. PMID: 19049336.

16. Ominsky MS, Vlasseros F, Jolette J, Smith SY, Stouch B, Doellgast G, et al. Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength. J Bone Miner Res. 2010; 25:948–959. PMID: 20200929.

17. Yang X, Han X, Shu R, Jiang F, Xu L, Xue C, et al. Effect of sclerostin removal in vivo on experimental periodontitis in mice. J Oral Sci. 2016; 58:271–276. PMID: 27349550.

18. Taut AD, Jin Q, Chung JH, Galindo-Moreno P, Yi ES, Sugai JV, et al. Sclerostin antibody stimulates bone regeneration after experimental periodontitis. J Bone Miner Res. 2013; 28:2347–2356. PMID: 23712325.